Eli Lilly faces societal obligation of GLP-1 drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly is facing a "societal obligation" regarding its GLP-1 medications, a key discussion point in the biotech sector.
- Merck has announced the acquisition of Terns Pharma, indicating strategic growth and investment.
- Former Loxo executives are gaining prominence at Lilly, suggesting a shift in leadership and potentially strategic direction within the company, as noted by STAT News.
Why it matters: Big Pharma is navigating drug accessibility and strategic acquisitions, shaping future health treatments.
Ask SkimNews
